Skip Navigation

Cardiovascular Research 1999 43(1):58-66; doi:10.1016/S0008-6363(98)00345-9
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Paraskevaidis, I. A
Right arrow Articles by Kremastinos, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paraskevaidis, I. A
Right arrow Articles by Kremastinos, D. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Assessment of the functional status of heart failure in non ischemic dilated cardiomyopathy: an echo-dobutamine study

Ioannis A Paraskevaidis*, Dimitrios P Tsiapras, Stamatis Adamopoulos and Dimitrios Th Kremastinos

2nd Department of Cardiology, Onassis Cardiac Surgery Center, 356 Sygrou Avenue, GR-17674 Athens, Greece

* Corresponding author. Tel.: +30-1-9406-184 or +30-1-9393-372; fax: +30-1-9393-373 or +30-1-9393-331. E-mail address: elbee@ath.forthnet.gr (I.A. Paraskevaidis)

Background: The functional status of heart failure (HF) is conventionally evaluated by peak exercise oxygen consumption (VO2 max). Dobutamine echocardiography can be used to evaluate myocardial reserve. The aim of this study was to estimate the functional status of chronic HF in patients with dilated cardiomyopathy, by investigating the changes in echo-variables, as assessed by echo-dobutamine, in relation with VO2 max. Methods and results: A low infusion rate echo-dobutamine test (10 µg/kg/min) was performed in 30 patients with dilated cardiomyopathy and 1 h later VO2 max was measured. VO2 max (ranging from 7.6 to 23 ml/kg/min, mean 14.06±0.64 ml/kg/min) was correlated with the changes (values obtained after inotropic stimulation minus those obtained at baseline) in left ventricular end-systolic diameter (r:0.80, p:0.001), in left ventricular end-systolic posterior wall thickness (r:0.73, p:0.001) and in left ventricular heart-rate corrected mean velocity of circumferential fiber shortening (Vcfc)/end-systolic meridional wall stress ratio (r:0.64, p:0.0001). A negative correlation was found between VO2 max and the changes in end-systolic meridional wall stress (r: –0.76, p:0.001). After dobutamine infusion Vcfc/systolic meridional wall stress ratio increased in patients with VO2 max >14 ml/kg/min but decreased in patients with VO2 max <14 ml/kg/min (0.0001±0.0001 vs –0.0002±0.0003 circxcm2/gxs, p:0.0001). End-systolic meridional wall stress was decreased in patients with VO2 max >14 ml/kg/min but increased in patients with VO2 max <14 ml/kg/min (–126.97±34.24 vs 205.77±56.71 g/cm2, p:0.0001). Conclusion: The changes in echo-variables assessed by echo-dobutamine are well correlated with VO2 max and seem to be accurate for evaluating the functional status of chronic HF in patients with dilated cardiomyopathy.

KEYWORDS Cardiomyopathy; Contractile function; Heart failure; Inotropic agents; Transplantation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.